Synspira’s PAAG15A receives orphan drug designation for cystic fibrosis treatment

Synspira Therapeutics’ investigational inhaled treatment, PAAG15A, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of cystic ... Read More